APP and Alzheimer disease: Nonetheless the mainstream research for AD therapies continues to be based on the amyloid cascade hypothesis and, as such, the leading molecular target has been for decades the beta-amyloid isoforms (Aβ), the cleavage product of the amyloid precursor protein (APP) [4] (Figure 1).